Photo of Samuel E. Gandy

Samuel E. Gandy

  • PROFESSOR Neurology
  • PROFESSOR Psychiatry
Print ProfilePrint Profile

Clinical Focus

Training Areas

Education

  • MD, Medical University of South Carolina

  • Internship, Internal Medicine
    Columbia University College of Physicians & Surgeons

  • Residency, Neurology
    New York Hospital Cornell University Med Ctr

Biography

    Sam Gandy, MD, PhD, is Mount Sinai Professor of Alzheimer's Disease Research, Professor of Neurology and Psychiatry, Associate Director of the Mount Sinai Alzheimer's Disease Research Center in New York City, and Chairman Emeritus of the National Medical and Scientific Advisory Council of the Alzheimer's Association. Dr. Gandy is an international expert in the metabolism of the sticky substance called amyloid that clogs the brain in patients with Alzheimer's. In 1989, Gandy and his team discovered the first drugs that could lower formation of amyloid. Dr. Gandy has written more than 150 original papers, chapters and reviews on this topic. Dr. Gandy has received continuous NIH funding for his research on amyloid metabolism since 1986.

    Dr. Gandy is a member of the Faculty of 1000 Biology and serves as a Consulting Editor for The Journal of Clinical Investigation.  He also serves on the Editorial Advisory Boards for the journals Public Library of Science-Medicine (PLoSM), Neurodegenerative Diseases, and Current Alzheimer Research.  He is Associate Editor of the journals Molecular Neurodegeneration and Alzheimer Disease and Associated Disorders. From 1996-2006, Dr Gandy was Director of the Cold Spring Harbor Laboratories/Wellcome Trust Annual Summer Course on the Neurobiology of Human Neurological Disorders. In 2000, he became chief organizer for the Cold Spring Harbor Laboratories Bi-Annual Winter Biotechnology Conference on Therapeutic Opportunities in Neurodegenerative Diseases and continues in that role until 2010.
    Dr. Gandy has appeared numerous times on television and in print, including:

    In May 2009, Dr. Gandy was featured with other prominent research scientists as GQ's "Rockstars of Science". View the PDF. In addition, Dr. Gandy has spoken before Congress on several occasions (Click to view the PDF of transcript of 5/3/05, PDF of transcript of 3/20/07)

    Dr. Gandy received both his MD and PhD at the Medical University of South Carolina. He completed an internship in Internal Medicine at the Columbia University College of Physicians & Surgeons and a residency in Neurology at Cornell University Medical College. Dr. Gandy completed postdoctoral training at The Rockefeller University, where, in 1991, he was appointed assistant professor in the laboratory of Paul Greengard, 2000 Laureate of the Nobel Prize in Physiology or Medicine. From 1992-1997, Gandy was Associate Professor of Neurology and Neuroscience at Cornell University Medical College. From 1997-2001, he was Professor of Psychiatry and of Cell Biology at New York University and The Nathan S. Kline Institute for Psychiatric Research. From 2001-2007, he served as Paul C. Brucker, M.D., Professor of Neuroscience at Jefferson Medical College and Founding Director of the Farber Institute for Neurosciences. In 2007, he assumed his current post as Mount Sinai Professor of Alzheimer's Disease Research at the Mount Sinai School of Medicine.

Awards

  • 2008 -
    Arthur Cherkin Memorial Award in Geriatric Medicine

Research

Current Students: John W. Steele IV, Hannah Brautigam

Postdoctoral Fellows: Soong Ho Kim, PhD, Rachel Lane, Ph.D.

Research Personnel: Alex Lublin, Ph.D. (Instructor), Carlos Thomas

Overview:
Dr. Gandy is an international expert in the metabolism of the substance called amyloid that clogs the brain in patients with Alzheimer's. In 1989, Gandy and his team discovered the first drugs that could lower formation of amyloid. Dr. Gandy has written more than 150 original papers, chapters and reviews on this topic. Dr. Gandy has received continuous NIH funding for his research on amyloid metabolism since 1986. Dr. Gandy is Professor of Alzheimer's Disease Research, Professor of Neurology and Psychiatry, and Associate Director of the Mount Sinai Alzheimer's Disease Research Center, and Chair, National Medical and Scientific Advisory Council of the Alzheimer's Association. 

Publications

Gandy S, Simon A, Steele J, Ehrlich M, E. Days-to-criterion as an indicator of toxicity of human Alzheimer amyloid-beta oligomers. Annals of Neurology 2010; DOI:10.1002/ana.22052.

Kim SH, Ehrlich ME, Gandy S, E. Group II metabotropic glutamate receptor stimulation triggers production and release of Alzheimer's amyloid-beta 42 from isolated intact nerve terminals.. The Journal of Neuroscience 2010; 30: 3870-3875.

Gandy S. Testing the amyloid hypothesis of Alzheimer's disease in vivo.. Lancet Neurology 2010; 9: 333-335.

Hata S, Gandy S, Suzuki T, E. Alcadein cleavages by amyloid-beta precursor protein (APP) alpha- and gamma-secretases generate small peptides, p3-Alcs, indicating gamma-secretase dysfunction.. The Journal of Biological Chemistry 2009; 284: 36024-36033.

Grathwohl SA, Gandy S, Aguzzi A, Staufenbiel M, Mathews PM, Wolburg H, Heppner FL, Jucker M, E. Formation and maintenance of Alzheimer's disease beta-amyloid plaques in the absence of microglia.. Nature Neuroscience 2009; 12: 1361-1363.

Gandy S, Doeven MK, Poolman B. Alzheimer disease: presenilin springs a leak. Nature Med 2006 Oct; 12(10): 1121-1123.

Small SA, Gandy S. Sorting through the cell biology of Alzheimer's disease: intracellular pathways to pathogenesis . Neuron 2006 Oct 5; 52(1): 15-31.

Gandy S. The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease . J Clin Invest 2005 May; 115(5): 1121-1129.

Gandy S, Naslund J, Nordstedt C. Alzheimer's disease. Molecular consequences of presenilin-1 mutation. Nature 2001 Jun; 411(6838): 654-656.

Xu H, Gouras GK, Greenfield JP, Vincent B, Naslund J, Mazzarelli L, Fried G, Jovanovic JN, Seeger M, Relkin NR, Liao F, Checler F, Buxbaum JD, Chait BT, Thinakaran G, Sisodia SS, Wang R, Greengard P, Gandy S. Estrogen reduces neuronal generation of Alzheimer beta-amyloid peptides. Nature Med 1998 Apr; 4(4): 447-451.

Lee MK, Borchelt DR, Kim G, Thinakaran G, Slunt HH, Ratovitski T, Martin LJ, Kittur A, Gandy S, Levey AI, Jenkins N, Copeland N, Price DL, Sisodia SS. Hyperaccumulation of FAD-linked presenilin 1 variants in vivo. Nature Med 1997 Jul; 3(7): 756-760.

Seeger M, Nordstedt C, Petanceska S, Kovacs DM, Gouras GK, Hahne S, Fraser P, Levesque L, Czernik AJ, George-Hyslop PS, Sisodia SS, Thinakaran G, Tanzi RE, Greengard P, Gandy S. Evidence for phosphorylation and oligomeric assembly of presenilin 1. Proc Natl Acad Sci U S A 1997 May 13; 94(10): 5090-5094.

Xu H, Sweeney D, Wang R, Thinakaran G, Lo AC, Sisodia SS, Greengard P, Gandy S. Generation of Alzheimer beta-amyloid protein in the trans-Golgi network in the apparent absence of vesicle formation. Proc Natl Acad Sci U S A 1997 Apr 15; 94(8): 3748-3752.

Borchelt DR, Thinakaran G, Eckman CB, Lee MK, Davenport F, Ratovitsky T, Prada CM, Kim G, Seekins S, Yager D, Slunt HH, Wang R, Seeger M, Levey AI, Gandy SE, Copeland NG, Jenkins NA, Price DL, Younkin SG, Sisodia SS. Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo . Neuron 1996 Nov; 17(5): 1005-1013.

Naslund J, Thyberg J, Tjernberg LO, Wernstedt C, Karlstrom AR, Bogdanovic N, Gandy SE, Lannfelt L, Terenius L, Nordstedt C. Characterization of stable complexes involving apolipoprotein E and the amyloid beta peptide in Alzheimer's disease brain . Neuron 1995 Jul; 15(1): 219-228.

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Below are financial relationships with industry reported by Dr. Gandy during 2012 and/or 2013. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Other Activities: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership.

  • Amicus Therapeutics, Inc.; Baxter; Constellation; Janssen Alzheimer Immunotherapy Research & Development, LLC

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.

Edit profile in Sinai Central

Mount Sinai Neurology Faculty Practice Associates

5 East 98th Street, 7th Floor
NYC, NY 10029

Tel: 212-241-7076
Get Directions